Signaling Pathway of Cannabidiol (CBD) for Prevention and Treatment of COVID-19

• Main Authors: Zhou, Zhongjun, Wong, Sheung Kin Ken, Zhou, Jie, Li, Cun, Ying, Leung Kris, Chu, Hin, Wang, Xuelai, Zhang, Jian
• Format: Patent
• Language: English
• Published: 02.06.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention relates to the technical field of medicine, and provides a method of screening and identifying small molecule with antiviral properties. The invention has screened and identified Cannabidiol (CBD), which can be used for prevention of viral infections. The invention also examined and verified that CBD can be used for prevention of COVID-19 disease, by a key signaling pathway of upregulating the expression of the TRIB3 gene. The invention also determined that the optimal dosage of CBD treatment for prevention of COVID-19 disease is 5 μM-10 μM.